ライフサイエンスコーパス: creatine phosphokinase

1 dition of oligomycin A, phosphocreatine, and creatine phosphokinase.

2 ach ferredoxin, ovalbumin, and rabbit muscle creatine phosphokinase.

3 -5 adverse events (AEs) were increased blood creatine phosphokinase (10.0% with cobimetinib plus atez

4 of 179), anaemia (ten [6%]), increased blood creatine phosphokinase (12 [7%]), and fatigue (eight [4%

5 t-related adverse events (AEs) were elevated creatine phosphokinase (24%), diarrhea (8%), and anemia

6 ients in the control group), increased blood creatine phosphokinase (51 [22%] vs 50 [18%]), and incre

7 ty population in either group were increased creatine phosphokinase (52 [19%] of 269 patients in the

8 AEs) were hair color changes (76%), elevated creatine phosphokinase (56%) and anemia (49%).

9 a (18%), hypertension (10%), increased blood creatine phosphokinase (9%), and lymphopenia (9%).

10 ce, and zinc supplementation decreased serum creatine phosphokinase activities and eliminated the dif

11 Serum creatine phosphokinase activity was significantly higher

12 hological changes, and the increase in serum creatine phosphokinase activity.

13 severity from grade 0 (preclinical; elevated creatine phosphokinase; all activities normal) to grade

14 ns of these factors, which lacked detectable creatine phosphokinase and ATPase activities, creatine p

15 ing I/R-induced increases in the activity of creatine phosphokinase and creatine kinase-MB.

16 min) induced an elevation in serum levels of creatine phosphokinase and myocardial injury characteriz

17 ick end labeling, (iii) a reduction in serum creatine phosphokinase, and (iv) improved weight gain.

18 rdiac lipid peroxidation, elevation of serum creatine phosphokinase, and functional changes in the is

19 elevated levels of muscle enzymes (aldolase, creatine phosphokinase, and lactate dehydrogenase).

20 age, disease duration, skin score, levels of creatine phosphokinase, and presence of tendon friction

21 ete blood count and electrolyte, creatinine, creatine phosphokinase, and troponin T levels were norma

22 Additionally, in 9 pigs, creatine phosphokinase (CK) activity in embolized myocar

23 CKM Glu83Gly (rs11559024) with constitutive creatine phosphokinase (CK) levels, CK variation, and in

24 ffect was an asymptomatic increase in plasma creatine phosphokinase concentration (200 mg, n=5; 400 m

25 ed a transient increase in the muscle enzyme creatine phosphokinase (CPK) 4 weeks after gene transfer

26 eficiency on muscle cells and the release of creatine phosphokinase (CPK) as a sequela of that defici

27 lity, time to microbiological clearance, and creatine phosphokinase (CPK) elevation.

28 Serial creatine phosphokinase (CPK)-MB levels were determined a

29 R (EC 1.5.1.3); (ii) transferase activity of creatine phosphokinase (EC 2.7.3.2) and hexokinase (EC 2

30 ts receiving vimseltinib was increased blood creatine phosphokinase (eight [10%] of 83).

31 vent in the upadacitinib group was increased creatine phosphokinase (eight [9%] of 93 patients in the

32 up vs six [4%] of 155 in the placebo group), creatine phosphokinase elevation (15 [4%] vs three [2%])

33 ryngitis (18 [12%] vs 22 [14%] vs 15 [10%]), creatine phosphokinase elevation (nine [6%] vs 13 [8%] v

34 s treatment-related adverse events occurred (creatine phosphokinase elevation attributed to antilipid

35 (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite

36 No cases of creatine phosphokinase elevations > or =10 times upper l

37 treatment is associated with moderate serum creatine phosphokinase elevations in up to 12% of patien

38 3 pravastatin and 7 placebo patients due to creatine phosphokinase elevations; no cases of mild or s

39 rade 3 or worse adverse events were elevated creatine phosphokinase (five [10%]) and maculopapular ra

40 es were uncommon, except for 15 increases in creatine phosphokinase in 14 participants (three partici

41 and one patient at 20 mg/kg, increased blood creatine phosphokinase in two patients at 20 mg/kg, and

42 in the placebo and vemurafenib group), blood creatine phosphokinase increase (30 [12%] vs one [<1%]),

43 patients: lymphopenia in two patients, blood creatine phosphokinase increase in one patient, aminotra

44 grade 4 occurred in one (2%) patient (blood creatine phosphokinase increase); no fatal events were r

45 ncreased (15 [25%] of 60 patients) and blood creatine phosphokinase increased (11 [18%]).

46 y grade in the atezolizumab group were blood creatine phosphokinase increased (123 [53%] of 231 patie

47 diarrhoea (157 [56%] of 280 patients), blood creatine phosphokinase increased (135 [48%]), and rash (

48 ncreased (15 [25%] of 60 patients) and blood creatine phosphokinase increased (ten [17%]).

49 most common being rash (80%, n = 24), blood creatine phosphokinase increased, diarrhea, and nausea (

50 ted the association of elevated troponin and creatine phosphokinase isoenzyme levels with mortality a

51 sthetic effects on extrarenal injury (plasma creatine phosphokinase, lactate dehydrogenase, and hemat

52 two groups (all p > 0.05), whereas the peak creatine phosphokinase level was significantly reduced i

53 Elevated temperature, an elevated creatine phosphokinase level, and autonomic dysfunction

54 or diarrhea; an asymptomatic increase in the creatine phosphokinase level; acneiform rash; and parony

55 vents were acne (16%), followed by increased creatine phosphokinase levels (13%) and increased lipids

56 atients, and 11 [4%] patients), elevation in creatine phosphokinase levels (16 [6%] patients, 16 [6%]

57 ck had lower ejection fractions, higher peak creatine phosphokinase levels (P < .0001), and more dise

58 f three recipients tested had elevated serum creatine phosphokinase levels and detectable serum myogl

59 Examination of serum creatine phosphokinase levels in these mice revealed sig

60 t infection, oral herpes, elevation of blood creatine phosphokinase levels, headache, and atopic derm

61 reduction in serum urea, creatinine, cardiac creatine phosphokinase-MB (CK-MB), and LDH levels.

62 Creatine phosphokinase-MB bands, troponin levels, and pu

63 the development of new pathologic Q waves or creatine phosphokinase-MB isoenzyme elevation >8 x upper

64 e transcripts including muscle mitochondrial creatine phosphokinase, muscle glycogen phosphorylase, h

65 nd 200 mg twice a day) and grade 4 increased creatine phosphokinase (n = 1; 150 mg once daily).

66 h autoimmune disorder (n=3), increased blood creatine phosphokinase (n=2), and increased aspartate am

67 [11%] in treatment group B), increased blood creatine phosphokinase (one [1%] vs four [4%]), and hypo

68 uch as age, diabetes, smoking history, serum creatine phosphokinase, or electrocardiographic findings

69 infarct size (p < 0.001), cardiac release of creatine phosphokinase (p < 0.001), and apoptotic cell d

70 Fenofibrate, but not LY518674, increased creatine phosphokinase (P = .004 vs placebo).

71 ction both in myocardial damage, assessed by creatine phosphokinase release, and in endothelial cell

72 sion improved cardiac function and decreased creatine phosphokinase release.

73 also improved cardiac function and decreased creatine phosphokinase release.

74 ough assessment of lactate dehydrogenase and creatine phosphokinase release.

75 dividuals had eye defects or elevated muscle creatine phosphokinase, separating the TMTC3 COB phenoty

76 laboratory values, including increased blood creatine phosphokinase (seven [8%]), increased alanine a

77 Creatine phosphokinase values were monitored and increas

78 ethnicity, skin score, serum creatinine and creatine phosphokinase values, hypothyroidism, and cardi

79 sthesia, abdominal pain, and increased blood creatine phosphokinase were more frequent with terifluno

80 stry appeared to be normal with exception of creatine phosphokinase, which peaked at 7 days after inf